Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated ...
In a recent review published in Signal Transduction and Targeted Therapy, researchers presented recombinant adeno-associated virus (rAAV)-based genetic applications to treat human diseases. Study: ...
Researchers from MIT have developed a bioreactor simulator to predict adeno-associated virus (AAV) yields for insect cell/baculovirus manufacturing. Francesco Destro, PhD, a postdoctoral associate ...
Although the targets of biomanufacturing have evolved from therapeutic proteins to āadvanced therapiesā and now to gene therapies, the issues and solutions remain the same. The production of safe, ...
The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene ...
Regenxbio and the University of Pennsylvania asserted a patent directed to recombinant host cells used in gene therapy. The claimed cells contain nucleic acid encoding a specific adeno-associated ...
PHILADELPHIA--(BUSINESS WIRE)--Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 ...
To generate successful gene therapies that are capable of delivering nucleic acids to specific cells and tissues, scientists must carefully design their products. They can employ either recombinant ...
In the mid-1990s, Hiroyuki Nakai, now an adeno-associated virus (AAV) researcher at the Oregon Health and Science University, moved to the United States. Nakai quickly became fascinated with the ...
Collaboration leverages AAV manufacturing expertise to advance a preclinical-stage gene therapy program for a rare pediatric neurological disorder.SAN SEBASTIÁN, Spain and LONDON, May 5, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results